GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » EV-to-EBIT

Nextage Therapeutics (XTAE:NXTG) EV-to-EBIT : -5.43 (As of May. 11, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nextage Therapeutics's Enterprise Value is ₪22.55 Mil. Nextage Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-4.15 Mil. Therefore, Nextage Therapeutics's EV-to-EBIT for today is -5.43.

The historical rank and industry rank for Nextage Therapeutics's EV-to-EBIT or its related term are showing as below:

XTAE:NXTG' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.79   Med: -2.12   Max: -0.68
Current: -5.43

During the past 8 years, the highest EV-to-EBIT of Nextage Therapeutics was -0.68. The lowest was -8.79. And the median was -2.12.

XTAE:NXTG's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.95 vs XTAE:NXTG: -5.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nextage Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was ₪10.28 Mil. Nextage Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-4.15 Mil. Nextage Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -40.41%.


Nextage Therapeutics EV-to-EBIT Historical Data

The historical data trend for Nextage Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics EV-to-EBIT Chart

Nextage Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial -5.03 -4.83 -7.28 -2.70 -2.47

Nextage Therapeutics Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.28 - -2.70 - -2.47

Competitive Comparison of Nextage Therapeutics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nextage Therapeutics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's EV-to-EBIT falls into.



Nextage Therapeutics EV-to-EBIT Calculation

Nextage Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22.552/-4.153
=-5.43

Nextage Therapeutics's current Enterprise Value is ₪22.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nextage Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-4.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nextage Therapeutics  (XTAE:NXTG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nextage Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-4.153/10.276981
=-40.41 %

Nextage Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was ₪10.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nextage Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-4.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nextage Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nextage Therapeutics (XTAE:NXTG) Business Description

Traded in Other Exchanges
N/A
Address
Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines